FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Expanded Use Cleared for Robotic Cochlear Implant Insertion

FDA clears an iotaMotion 510(k) for an expanded pediatric indication for its iotaSOFT robotic-assisted cochlear implant insertion system.

latest-news-card-1
Human Drugs

Sclerotic FDA Shuns Innovation: Column

Taxpayers Protection Alliance executive director Ross Marchand says FDA needs to change its risk-averse approach to drug evaluation and accelerate app...

latest-news-card-1
Human Drugs

CGMP Issues Seen in Winder Laboratories Inspection

FDA warns Winder, GA-based Winder Laboratories about repeat CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Biologics

Vyvgart sBLA Seeks Expanded Use

FDA accepts for priority review an Argenx supplemental BLA seeking to expand the use of its myasthenia gravis drug Vyvgart.

latest-news-card-1
Human Drugs

FDA Quietly Retires Autism Bogus Therapies Page

An Ars Technica post says FDA has dropped a Web page that listed some specific bogus autism treatments and therapies and warned of their potential hea...

latest-news-card-1
Human Drugs

Remove Suicide Warning from GLP-1 Drugs: FDA

FDA says Novo Nordisk and Lilly should remove statements about the potential for suicidal ideation and behavior from labeling for their weight loss dr...

latest-news-card-1

Ways for FDA to Modernize Biotech Regulation

The National Security Commission on Emerging Biotechnology recommends 22 policy actions in five key areas to modernize FDA medical biotechnology regul...

latest-news-card-1
Biologics

PharmaEssentia Besremi sBLA for Essential Thrombocythemia.

FDA accepts for review a PharmaEssentia supplemental BLA seeking to expand the label of its interferon therapy Besremi to include adults with essentia...

latest-news-card-1
FDA General

Pazdur Warns About Political Interference, Upheaval At FDA

Former FDA Oncology Center for Excellence director Richard Pazdur warns that political interference and internal upheaval are eroding the agencys abil...

latest-news-card-1
Human Drugs

FDA Extends Review for Filspari in Kidney Disease

FDA extends by three months its review of a Travere Therapeutics supplemental NDA for Filspari in focal segmental glomerulosclerosis.